To serve our readership better, future editions of Therapeutics and Clinical Risk
Management will once again feature the Editor's comments and views on some of the …

Abstract Background: According to the 2010 Osteoporosis Canada Clinical Practice
Guidelines, denosumab is a first-line option for the pharmacological management of …

Denosumab (Prolia®) is a human recombinant monoclonal antibody that is approved for the
treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in …

Postmenopausal osteoporosis is a major concern to public health. Fractures are the major
clinical consequence of osteoporosis and are associated with substantial morbidity …

The pathway of the receptor activator of the nuclear factor κ B ligand (RANKL), RANK and
osteoprotegerin (OPG) plays a central role in coupling bone formation and resorption during …

Abstract Subcutaneous denosumab (Prolia®[USA, Europe]; Pralia®[Japan]) once every 6
months is indicated in several countries for the treatment of postmenopausal women with …

Denosumab (Prolia®) is a human recombinant monoclonal antibody that is approved for the
treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in …

Osteoporosis is a skeletal disorder characterized by compromised bone strength, leading to
bone fragility with increased vulnerability to fracture. Of the 10 million Americans estimated …

OBJECTIVE: To review the evidence for use of denosumab for the treatment of
postmenopausal osteoporosis. DATA SOURCES: A search of MEDLINE and EMBASE …

Abstract Denosumab (Prolia®; Pralia®) is a human monoclonal antibody targeting the key
bone resorption mediator RANKL. The drug is administered via subcutaneous injection once …